We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
Cap. Flow
-$10.2M
Cap. Flow %
-0.22%
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$54.7M
2
EAR
Eargo, Inc. Common Stock
EAR
+$37.9M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$37.2M
4
SPRB
Spruce Biosciences
SPRB
+$36M
5
LUNG icon
Pulmonx
LUNG
+$24.5M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$135M
2
CNC icon
Centene
CNC
+$37.5M
3
BAX icon
Baxter International
BAX
+$27.2M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.1M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 92.97%
2 Consumer Staples 1.52%
3 Consumer Discretionary 0.76%
4 Industrials 0.46%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
126
MacroGenics
MGNX
$259M
$7.08M 0.15%
309,510
+46,869
+18% +$1.08M
OSW icon
127
OneSpaWorld
OSW
$2.62B
$7M 0.15%
690,000
-1,050,000
-60% -$8.3M
CNST
128
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$6.7M 0.14%
232,743
-282,937
-55% -$7.12M
ANAB icon
129
AnaptysBio
ANAB
$1.64B
$6.65M 0.14%
309,413
+300
+0.1% +$7.29K
GRTX
130
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$5.81M 0.12%
567,552
– –
ITOS
131
DELISTED
iTeos Therapeutics
ITOS
$5.41M 0.11%
159,957
-66,724
-29% -$1.77M
HQY icon
132
HealthEquity
HQY
$8.93B
$5.23M 0.11%
75,000
-285,100
-79% -$17.7M
PANA.U
133
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$5.13M 0.11%
402,088
– –
CERT icon
134
Certara
CERT
$1.23B
$5.06M 0.11%
+150,000
New +$5.49M
TLPH icon
135
Talphera
TLPH
$73.2M
$4.69M 0.1%
189,123
+444
+0.2% +$13.6K
PHAS
136
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$4.42M 0.09%
1,314,374
+1,200
+0.1% +$4.3K
BLSA
137
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.44M 0.07%
+309,000
New +$3.31M
PSTX
138
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.18M 0.07%
289,754
-77,745
-21% -$820K
CO
139
DELISTED
Global Cord Blood Corporation
CO
$2.88M 0.06%
775,000
-129,800
-14% -$498K
SNCE
140
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.2M 0.05%
+10,310
New +$2.14M
EUCRU
141
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.2M 0.05%
+206,000
New +$2.09M
JYAC
142
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.12M 0.05%
+206,200
New +$2.1M
TMPMU
143
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$2.12M 0.04%
+206,000
New +$2.09M
PHICU
144
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
$2.1M 0.04%
+201,044
New +$2.07M
MLTX icon
145
MoonLake Immunotherapeutics
MLTX
$1.47B
$1.76M 0.04%
+154,500
New +$1.64M
ANNX icon
146
Annexon
ANNX
$883M
$1.14M 0.02%
45,413
-191,398
-81% -$4.93M
APRE icon
147
Aprea Therapeutics
APRE
$7.98M
– –
-25,915
Closed -$12.5M
ASMB icon
148
Assembly Biosciences
ASMB
$530M
– –
-121,993
Closed -$24.1M
CYTK icon
149
Cytokinetics
CYTK
$10.8B
– –
-206,495
Closed -$4.47M
GDRX icon
150
GoodRx Holdings
GDRX
$1.25B
– –
-100,000
Closed -$5.56M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
  • Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
  • Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
  • Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
  • Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.